RNAC

Oppenheimer Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

Fintel reports that on June 4, 2024, Oppenheimer initiated coverage of Cartesian Therapeutics (NasdaqGM:RNAC) with a Outperform recommendation.

Analyst Price Forecast Suggests 20.70% Upside

As of June 1, 2024, the average one-year price target for Cartesian Therapeutics is 43.45. The forecasts range from a low of 38.38 to a high of $56.70. The average price target represents an increase of 20.70% from its latest reported closing price of 36.00.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Cartesian Therapeutics is 42MM, an increase of 62.15%. The projected annual non-GAAP EPS is -0.18.

What is the Fund Sentiment?

There are 158 funds or institutions reporting positions in Cartesian Therapeutics. This is an decrease of 23 owner(s) or 12.71% in the last quarter. Average portfolio weight of all funds dedicated to RNAC is 0.01%, an increase of 69.85%. Total shares owned by institutions increased in the last three months by 3.81% to 55,512K shares. RNAC / Cartesian Therapeutics, Inc. Put/Call Ratios The put/call ratio of RNAC is 0.00, indicating a bullish outlook.

What are Other Shareholders Doing?

RNAC / Cartesian Therapeutics, Inc. Shares Held by Institutions

FBIOX - Biotechnology Portfolio holds 10,917K shares representing 61.35% ownership of the company. In its prior filing, the firm reported owning 5,386K shares , representing an increase of 50.67%. The firm decreased its portfolio allocation in RNAC by 10.30% over the last quarter.

Artal Group holds 9,137K shares representing 51.34% ownership of the company. No change in the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,799K shares representing 21.35% ownership of the company. No change in the last quarter.

IWM - iShares Russell 2000 ETF holds 2,619K shares representing 14.72% ownership of the company. In its prior filing, the firm reported owning 2,829K shares , representing a decrease of 8.00%. The firm decreased its portfolio allocation in RNAC by 10.10% over the last quarter.

Geode Capital Management holds 2,499K shares representing 14.04% ownership of the company. In its prior filing, the firm reported owning 2,438K shares , representing an increase of 2.43%. The firm decreased its portfolio allocation in RNAC by 13.21% over the last quarter.

Cartesian Therapeutics Background Information
(This description is provided by the company.)

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.